My current research is largely focused on molecularly targeted cancer therapeutics, personalized cancer medicine, and epigenetic mechanisms of drug resistance. I am especially interested in developing a better understanding of the nature of dynamic fluctuation of phenotypic states within tumor cell subpopulations, and the role the consequent heterogeneity plays in tumor evolution, response to drug treatment, and other stressful exposures.
I was a postdoctoral fellow at the Whitehead Institute for Biomedical Research at M.I.T. in Bob Weinberg’s laboratory, before joining the Harvard School of Medicine faculty in 1992. During my 18 years on the Harvard faculty, I was named the Laurel Schwartz Professor of Oncology, I served as Director of the Center for Molecular Therapeutics and Scientific Director of the Massachusetts General Hospital Cancer Center, and led the Cancer Cell Biology program of the Dana Farber Harvard Cancer Center. From 2010-2015, I was the Senior Director of Discovery Oncology at Genentech, before moving to Calico in 2015.